title: [Rivastigmine in a case of autopsy proved frontotemporal dementia (Pick's disease)].
abstract: BACKGROUND
  Cholinesterase inhibitors are useful in the treatment of behavioural and psychological symptoms in Alzheimer's disease. Their effectiveness in frontotemporal dementia has not been proved, since such a claim has only been backed by the publication of one open-label trial in which the behavioural and psychological symptoms of the patients treated with rivastigmine over a 12-month period improved significantly with respect to those belonging to a group that were given a placebo. We report a case of frontotemporal dementia, Pick's disease, which improved with rivastigmine treatment.
  
  
  METHODS
  A 61-year-old male who presented a progressive clinical picture of behavioural disorders and executive-cognitive impairment that had begun two years earlier. Magnetic resonance imaging of the head revealed severe frontotemporal atrophy. Neuropsychological Inventory (NPI). Overall score 36/144 (6/12: anxiety, disinhibition and aberrant motor behaviour, 4/12: agitation, irritability and apathy; 3/12: sleep and eating disorders. After three months' treatment with rivastigmine, the overall score on the NPI was 10/144. This improvement remained stable over the months that followed. The patient died eight months later after developing liver cancer with metastasis. The microscopic study of the brain showed tau-positive neuronal inclusions, gliosis and neuronal loss. The inclusions were well-circumscribed Pick bodies, which were present in the frontal and temporal cortices and in the dentate gyrus of the hippocampus.
  
  
  CONCLUSIONS
  This case confirms the idea that treatment with cholinesterase inhibitors can be effective in the behavioural and psychological symptoms of frontotemporal dementia.
authors.affiliation: Servicio de Neurología, Hospital Universitario Central de Asturias, Oviedo, Spain. tcalatayudn@gmail.com
authors.forename: T
authors.initials: T
authors.lastname: Calatayud-Noguera
authors.forename: A
authors.initials: A
authors.lastname: Astudillo-González
authors.forename: J C
authors.initials: JC
authors.lastname: Alvarez-Carriles
authors.forename: T
authors.initials: T
authors.lastname: Temprano-Fernández
authors.forename: M
authors.initials: M
authors.lastname: Cortés-Velarde
authors.forename: P
authors.initials: P
authors.lastname: Oliva-Nacarino
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D001344:Autopsy; D001921:Brain / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates / Q000627:therapeutic use*; D020774:Pick Disease of the Brain / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine